Navigation path


Development of antibiofilm coatings for implants
EC contribution
: € 2.999.936
: 48 months
Starting date
: 01/01/2012
Funding scheme
: SME-targeted Collaborative Project
: biofilm prevention, biofilm eradication, bacterial and fungal pathogens, proprietary antibiofilm molecules, mode of antibiofilm action, orthopaedic implant, dental implant, non-releasing coating, osseointegration
Contract/Grant agreement number
: 278425
Project web-site


The aim of the SME-driven COATIM consortium is to tackle the increasing problem of infections due to biofilms, groups of microorganisms that stick together on different surfaces within the human body and escape conventional antibiotic treatment. Biofilms are typically found on medical devices like implants. Until now, biocidal implant coatings have been developed that are based on either the release of silver ions, which are toxic upon accumulation, or on conventional antibiotics that have poor activity against microorganisms in biofilms. Therefore, COATIM aims to develop the next generation of implant coatings containing novel proprietary antibiofilm molecules, either peptides or small molecules, with inhibitory activity against microbial biofilms.

COATIM contributes to a dynamic and competitive knowledge based economy, sustainable development, and serves the needs of the SME-intensive medical technology products market in Europe.


The most recent generation of implants with open porosity enable fast osseointegration, but also present an increased risk of microbial biofilm-associated infection. Biofilm-associated infections are responsible for 15-25% of implant failure, and necessitate burdensome and costly revision surgery. The latter is estimated to represent a supplementary medical cost of €800m/year in Europe without taking into account the pain and distress of the patients, indicating that any significant reduction of this type of implant failure is highly recommended.

[+] Read More